Detection of BRAF Mutations in Tumour and Serum

Detection of BRAF Mutations in Tumour and Serum

Detection of BRAF Mutations in Tumour and Serum of Patients with Advanced Melanoma Dr Ruth Board CMGS Spring Scientific Conference March 26th 27th 2009 AZD6244 Introduction BRAF+, BRAF mutation positive BRAF mutations occur in up to 60% of cutaneous melanomas AZD6244 (ARRY-142886) is an orally available, potent, selective, ATPuncompetitive inhibitor of MEK1/2, a downstream activator of BRAF AZD6244 has shown

preclinical activity in BRAF+ tumour models AZD6244 Phase II study of AZD6244 vs temozolomide in patients with advanced melanoma (study D1532C00003) First-line advanced melanoma patients randomised (n = 200) AZD6244 100 mg BID continuously Temozolomide 200 mg/m2 for 5 days, q28d Investigator choice of therapy Investigator choice of therapy May receive AZD6244

PFS (primary endpoint) Follow up for overall survival Primary Objective: To compare the efficacy of AZD6244 versus temozolomide by evaluation of: (i) primary outcome variable PFS using site measurements and (ii) secondary outcome variables, including overall survival and response rate 6 patients randomised to AZD6244 had a clinical response, 5 of whom had BRAF+ tumour AZD6244 Mutation detection in tumour samples Invasive procedure Access to tumour samples

Often archival, FFPE Often at multiple hospitals, difficult and slow to access Requires further processing and 34 days extraction DNA from FFPE samples often poor quality and low yield Mutation status of archival tumour may not reflect current mutational status Emergence of EGFR resistance mutations Heterogeneous nature of tumour samples Differences in mutations between sites of metastases and within metastases EGFR, epidermal growth factor receptor; FFPE, formalin fixed paraffin embedded AZD6244 cfDNA as an alternative to tumour biopsies Increased levels of cfDNA are detected in the blood of patients with cancer Source and mechanism of DNA release remains unclear

Fleischhacker M & Schmidt B. Nature Medicine 2008; 14:914915 Direct shedding from tumours or from CTCs Previous studies have shown that it is possible to detect tumourspecific mutations in cfDNA Provides the opportunity to develop mutation detection tests which are: less invasive quicker to process real time assessment cfDNA, circulating free DNA; CTCs, circulating tumour cells AZD6244 Study design

Access to 126 serum samples from patients enrolled in the AZD6244 Phase II advanced melanoma study Included 94 cases with known BRAF tumour data 47.9% BRAF+ The aim of this study was to assess the feasibility of using cfDNA for BRAF mutation detection in patients with advanced melanoma AZD6244 Allele specific PCR T A g. 1799T>A mutation present Perfect match and primer extension

T T No mutation present Mismatch - no primer extension or product Product detected by Taqman probe AZD6244 Allele specific PCR T T A T g. 1799T>A mutation present No mutation present

Perfect match and primer extension Mismatch - no primer extension or product Product detected by Taqman probe Control: Diagnostic: + + + AZD6244 BRAF mutation detection in cfDNA Tumour DNA cfDNA Total

BRAF+ n (%) No BRAF mutation n (%) BRAF unknown n (%) Total (%) BRAF+ 25 (56) 3 (6) 5 (16) 33 (26) No BRAF mutation 20 (44) 46 (94)

27 (84) 93 (74) 45 49 32 126 AZD6244 Questions Does the presence of a serum BRAF mutation reflect prognosis? If patients are pre-selected on the basis of serum BRAF status, will this enrich for a population of patients with a worse outcome and/or poorer prognostic factors? AZD6244 The presence of circulating BRAF

mutations does not affect PFS* BRAF+ on tumour only BRAF+ on tumour and cfDNA HR 1.08 (80% CI 0.69, 1.68; two-sided p=0.826) *In those patients with BRAF+ tumours where serum was available for analysis HR calculated using an unadjusted Cox proportional hazards model AZD6244 Does having BRAF positive cfDNA correlate with known prognostic factors? 126 cfDNA patients: serum mutation result BRAF+ n = 33 (%) BRAF unknown n = 93 (%) Total population in Phase II advanced melanoma study n = 200 (%) LDH < 2xULN 24 (73) 82 (88) 158 (79) LDH 2xULN 8 (24) 8 (9) 32 (16) LDH AZD6244 Conclusions We have demonstrated the potential to use cfDNA for BRAF mutation detection in patients with advanced melanoma Future work will include:

Further validation of cfDNA as an alternative to tissue biopsies Use of plasma derived cfDNA Alternative technologies for mutation detection Other cancer types and mutations AZD6244 Acknowledgements AstraZeneca R&D Genetics Laura Blockley Gillian Ellison Simon Dearden Emma Donald Gael McWalter

Vicky Williams PhD supervisors Caroline Dive Malcolm Ranson Andrew Hughes AZD6244 study team Maria Orr Mireille Cantarini Karin Kemsley Clive Morris All of the patients and investigators involved in the AZD6244 Phase II trial in advanced melanoma (study 3) AZD6244

Recently Viewed Presentations

  • Demonstration - skynet.heartlandtower.com

    Demonstration - skynet.heartlandtower.com

    Hardware Home station requirements 2 meter radio and antenna Desktop computer TNC or soundcard/interface Mobile station requirements 2 meter radio and antenna Variables Hardware Mobile variables - Track & View GPS Laptop TNC Hardware Mobile variables - Mobile Tracking GPS...
  • Affordance Detection for Task-Specific Grasping Using Deep ...

    Affordance Detection for Task-Specific Grasping Using Deep ...

    Main idea: model relations between object, task and a grasp, using object affordances. Use convolutional neural networks (CNNs) for object affordance detection for task-specific grasping on full and partial point clouds. Encode object affordances, object class, and object orientation to...
  • Normalcy for Children and Youth in Foster Care:

    Normalcy for Children and Youth in Foster Care:

    While foster caregivers are obviously the designated RPP (reasonable and prudent parent) for their household, group homes (CCIs) are required to designate a person to be their RPP designee. This person is empowered the same as family foster caregiver to...
  • Extending Oblivious Transfers Efficiently Yuval Ishai Technion Joe

    Extending Oblivious Transfers Efficiently Yuval Ishai Technion Joe

    Since OT implies key exchange, it must be at least as expensive and its implementations involve costly operations such as modular exponentiations. As a result, OT's form the efficiency bottlneck in most protocols where they are used, and counting oblivious...
  • Rhetorical Devices

    Rhetorical Devices

    METAPHOR. Metaphor compares two different things in a figurative sense. Unlike in a simile (A is like B.), "like" is not used in metaphor (A is B.): Truthsare first clouds, then rain, then harvest and food. (Henry Ward Beecher) Through...
  • IN YOUR FACE Anish Mathur Brian Thompson Sunny

    IN YOUR FACE Anish Mathur Brian Thompson Sunny

    Concept This project allows individuals to view customizable information right in their mirror without interrupting any usual activities. The prototype features a LCD screen controlled by a Wi-Fi enabled computer, delivering RSS Feeds directly to a user's mirror, while allowing...
  • Multi-Frame Plane Alignment

    Multi-Frame Plane Alignment

    Geometric info Video Browsing, Indexing, and Manipulation [work with P. Anandan, S. Hsu, T. Hassner] INTERACTIVE DEMO Sequence 1 Sequence 2 Frame 1 Frame 2 Frame 3 Frame n Frame 1 Frame 2 Frame 3 Frame n Sequence-to-Sequence Alignment [work...
  • Nationalised PPT on Goods &amp; Services Tax (GST)

    Nationalised PPT on Goods & Services Tax (GST)

    Concept of Electronic Focal Point Branch (E-FPB) E-FPB are branches of authorized banks designated to collect payment of GST. Each authorized bank will nominate only one branch as its E-FPB for pan India Transactions.